Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
Hsiao-Yen Ma, Jason A. Vander Heiden, Salil Uttarwar, Ying Xi, Elsa-Noah N'Diaye, Ryan LaCanna, Patrick Caplazi, Sarah Gierke, John Moffat, Paul J. Wolters, Ning Ding
Source: Eur Respir J, 61 (4) 2200604; 10.1183/13993003.00604-2022
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Hsiao-Yen Ma, Jason A. Vander Heiden, Salil Uttarwar, Ying Xi, Elsa-Noah N'Diaye, Ryan LaCanna, Patrick Caplazi, Sarah Gierke, John Moffat, Paul J. Wolters, Ning Ding. Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. Eur Respir J, 61 (4) 2200604; 10.1183/13993003.00604-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
|
|